Anavex Life Sciences Corp. is facing a class action lawsuit for alleged securities fraud, following the termination of its CEO and the disclosure of a material weakness in internal controls.
Why it matters. Investors in Anavex may be affected by the lawsuit, which could impact the company's stock price and operations.
that there was a material weakness in internal control over financial reporting that existed at September 30, 2025
Anavex's stock price fell $0.22 per share, or 6.59%, to clos at $3.12 per share on May 7, 2026.
On this news, Anavex's stock price fell $0.19 per share, or 6.35%, to close at $2.80 per share on August 31, 2026
the Company's disclosure controls and procedures were not effective as of September 30, 2025
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Anavex Life Sciences Corp.
Then, on August 28, 2026, Anavex filed with the SEC an amended Annual Report on Form 10-K/A for the fiscal year ended September 30, 2025 (the "Amended 2025 Annual Report"), which disclosed management's conclusion "that there was a material weakness in internal control over finan…
